NBTX - Nanobiotix
Nanobiotix Logo

NBTX - Nanobiotix

https://www.nanobiotix.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.

52W High
$10.59
52W Low
$2.76
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.58
Valuation
Rich
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
48.31
EV/EBITDA (<8 favorable)
-2.45
EV/Revenue (<3 favorable)
3.39
P/S (TTM) (<3 favorable)
3.82
P/B (<3 favorable)
65.02
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
11.90%
Shares Outstanding
47,921,000
Float
24,806,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-03-31 (Overview)
Revenue (TTM)
-7,190,000
Gross Profit (TTM)
-7,190,000
EPS (TTM)
-1.68
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
2.71%
ROE (TTM) (>15% strong)
-1.99%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
1.82
Momentum
Bearish momentum
Value
0.6456
Previous
0.6270
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025